Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CSII's Cash to Debt is ranked higher than
94% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. CSII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CSII' s Cash to Debt Range Over the Past 10 Years
Min: 1.11  Med: 369.07 Max: No Debt
Current: No Debt
Equity to Asset 0.71
CSII's Equity to Asset is ranked higher than
65% of the 292 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. CSII: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
CSII' s Equity to Asset Range Over the Past 10 Years
Min: -1.4  Med: 0.52 Max: 0.87
Current: 0.71
-1.4
0.87
F-Score: 4
Z-Score: 8.41
M-Score: -3.87
WACC vs ROIC
21.84%
-118.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -31.47
CSII's Operating margin (%) is ranked lower than
69% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. CSII: -31.47 )
Ranked among companies with meaningful Operating margin (%) only.
CSII' s Operating margin (%) Range Over the Past 10 Years
Min: -60.63  Med: -21.58 Max: 3.82
Current: -31.47
-60.63
3.82
Net-margin (%) -31.44
CSII's Net-margin (%) is ranked lower than
69% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. CSII: -31.44 )
Ranked among companies with meaningful Net-margin (%) only.
CSII' s Net-margin (%) Range Over the Past 10 Years
Min: -56.49  Med: -23.14 Max: 13.13
Current: -31.44
-56.49
13.13
ROE (%) -47.16
CSII's ROE (%) is ranked lower than
76% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. CSII: -47.16 )
Ranked among companies with meaningful ROE (%) only.
CSII' s ROE (%) Range Over the Past 10 Years
Min: -99.5  Med: -47.59 Max: 10
Current: -47.16
-99.5
10
ROA (%) -36.27
CSII's ROA (%) is ranked lower than
74% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. CSII: -36.27 )
Ranked among companies with meaningful ROA (%) only.
CSII' s ROA (%) Range Over the Past 10 Years
Min: -58.12  Med: -30.3 Max: 6.68
Current: -36.27
-58.12
6.68
ROC (Joel Greenblatt) (%) -120.47
CSII's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. CSII: -120.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CSII' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4509.29  Med: -177.88 Max: 88.2
Current: -120.47
-4509.29
88.2
Revenue Growth (3Y)(%) 4.60
CSII's Revenue Growth (3Y)(%) is ranked higher than
52% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. CSII: 4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CSII' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -7 Max: 23.9
Current: 4.6
0
23.9
EBITDA Growth (3Y)(%) 16.90
CSII's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CSII: 16.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CSII' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -27.5 Max: 79.4
Current: 16.9
0
79.4
EPS Growth (3Y)(%) 15.70
CSII's EPS Growth (3Y)(%) is ranked higher than
69% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. CSII: 15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CSII' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: -9.05 Max: 81.2
Current: 15.7
-66.2
81.2
» CSII's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CSII Guru Trades in Q3 2015

Jim Simons 126,539 sh (New)
Mairs and Power 207,632 sh (+54.74%)
Mario Gabelli 33,500 sh (+34.00%)
Paul Tudor Jones Sold Out
Steven Cohen 42,800 sh (-88.34%)
» More
Q4 2015

CSII Guru Trades in Q4 2015

Jim Simons 167,200 sh (+32.13%)
Mairs and Power 246,202 sh (+18.58%)
Mario Gabelli 35,200 sh (+5.07%)
Steven Cohen Sold Out
» More
Q1 2016

CSII Guru Trades in Q1 2016

Paul Tudor Jones 10,900 sh (New)
Steven Cohen 102,200 sh (New)
Mario Gabelli 36,300 sh (+3.13%)
Mairs and Power 246,202 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

CSII Guru Trades in Q2 2016

Steven Cohen 403,824 sh (+295.13%)
Mario Gabelli 36,400 sh (+0.28%)
Paul Tudor Jones Sold Out
Mairs and Power 121,202 sh (-50.77%)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:OFIX, NAS:KTWO, NYSE:ITGR, NAS:VASC, OTCPK:SBMAF, NYSE:CRY, NAS:MDXG, NAS:HTWR, OTCPK:MZRTF, NAS:GNMK, NAS:SPNC, OTCPK:BSNRY, NAS:ARAY, NAS:XENT, NAS:CNMD, NAS:EXAC, NYSE:IVC, NAS:INGN, NAS:CYNO, NAS:AXGN » details
Traded in other countries:R7Y1.Germany,
Cardiovascular Systems Inc is a medical technology company. It is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases.

Cardiovascular Systems Inc was incorporated as Replidyne, Inc. in Delaware in 2000. It is a medical technology company. The Company is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases. It treats patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium, the difficult arterial disease to treat. The Company is committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve lives of patients facing this difficult disease state. Its product s include Diamondback 360 Peripheral, Predator 36, Stealth 360, Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral. It competes with Abbott Laboratories, Boston Scientific, Cook Medical, Johnson & Johnson, BARD, and Medtronic. It also competes against manufacturers of atherectomy catheters including Medtronic, Spectranetics, Boston Scientific and Philips. The Company held approximately 46 issued U.S. patents and have approximately 39U.S.patent applications pending, as well as approximately 203 issued or granted foreign patents and approximately 148 foreign patent applications, each of which corresponds to aspects of its U.S. patents and applications. The Company have received 18 federal registrations in the U.S. Patent and Trademark Office of certain marks, including Diamondback, a first CSI, second CSI, Predator 360, Stealth 360, a first CSI logo, a second CSI logo, Lumen Library, Viper Wire, Viper Wire Advance, Viper slide, Viper Track, Viper Caddy, Stealth 360, a first Diamondback 360, a second Diamondback 360, Diamondback 360 (Stylized) Logo, and Stay A Step Ahead of PAD.

Guru Investment Theses on Cardiovascular Systems Inc

Mairs & Power Small Cap Fund Comments on Cardiovascular Systems - Oct 20, 2014

During the quarter, the Fund added medical device maker Cardiovascular Systems (CSII), one of the few remaining small public medical device companies based in the Twin Cities. The company has a strong position in treating peripheral arterial disease with its proprietary atherectomy equipment. A recent approval in significantly calcified coronary arteries opens up a substantial new market opportunity that the company is working hard to commercialize.



From Mairs & Power Small Cap Fund Q3 2014 Commentary.



Check out Bill Frels latest stock trades

Ratios

vs
industry
vs
history
P/B 7.47
CSII's P/B is ranked lower than
83% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. CSII: 7.47 )
Ranked among companies with meaningful P/B only.
CSII' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 5.48 Max: 14.5
Current: 7.47
0.18
14.5
P/S 4.20
CSII's P/S is ranked lower than
63% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. CSII: 4.20 )
Ranked among companies with meaningful P/S only.
CSII' s P/S Range Over the Past 10 Years
Min: 0.24  Med: 2.28 Max: 7.39
Current: 4.2
0.24
7.39
EV-to-EBIT -12.60
CSII's EV-to-EBIT is ranked lower than
99.99% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 21.78 vs. CSII: -12.60 )
Ranked among companies with meaningful EV-to-EBIT only.
CSII' s EV-to-EBIT Range Over the Past 10 Years
Min: -35.1  Med: -12.9 Max: 9.1
Current: -12.6
-35.1
9.1
EV-to-EBITDA -13.54
CSII's EV-to-EBITDA is ranked lower than
99.99% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 16.76 vs. CSII: -13.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
CSII' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37  Med: -11 Max: 6.7
Current: -13.54
-37
6.7
Current Ratio 2.95
CSII's Current Ratio is ranked higher than
57% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. CSII: 2.95 )
Ranked among companies with meaningful Current Ratio only.
CSII' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 4.01 Max: 9.99
Current: 2.95
1.27
9.99
Quick Ratio 2.46
CSII's Quick Ratio is ranked higher than
59% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. CSII: 2.46 )
Ranked among companies with meaningful Quick Ratio only.
CSII' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 3.73 Max: 9.99
Current: 2.46
1.18
9.99
Days Inventory 171.71
CSII's Days Inventory is ranked lower than
67% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 132.94 vs. CSII: 171.71 )
Ranked among companies with meaningful Days Inventory only.
CSII' s Days Inventory Range Over the Past 10 Years
Min: 37.97  Med: 113.08 Max: 171.71
Current: 171.71
37.97
171.71
Days Sales Outstanding 47.38
CSII's Days Sales Outstanding is ranked higher than
79% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. CSII: 47.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
CSII' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.38  Med: 55.96 Max: 61.98
Current: 47.38
47.38
61.98
Days Payable 87.65
CSII's Days Payable is ranked higher than
66% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. CSII: 87.65 )
Ranked among companies with meaningful Days Payable only.
CSII' s Days Payable Range Over the Past 10 Years
Min: 81.57  Med: 106.82 Max: 116.18
Current: 87.65
81.57
116.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.40
CSII's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. CSII: -10.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CSII' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -242.8  Med: -47.9 Max: -10.4
Current: -10.4
-242.8
-10.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.33
CSII's Price/Net Cash is ranked lower than
77% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 15.46 vs. CSII: 38.33 )
Ranked among companies with meaningful Price/Net Cash only.
CSII' s Price/Net Cash Range Over the Past 10 Years
Min: 0.62  Med: 11.85 Max: 42.57
Current: 38.33
0.62
42.57
Price/Net Current Asset Value 11.91
CSII's Price/Net Current Asset Value is ranked lower than
71% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.14 vs. CSII: 11.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CSII' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.6  Med: 7.31 Max: 27.54
Current: 11.91
0.6
27.54
Price/Tangible Book 7.87
CSII's Price/Tangible Book is ranked lower than
74% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.38 vs. CSII: 7.87 )
Ranked among companies with meaningful Price/Tangible Book only.
CSII' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.6  Med: 6.25 Max: 12.81
Current: 7.87
0.6
12.81
Price/Median PS Value 1.84
CSII's Price/Median PS Value is ranked lower than
85% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. CSII: 1.84 )
Ranked among companies with meaningful Price/Median PS Value only.
CSII' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 1.17 Max: 2.76
Current: 1.84
0.45
2.76
Earnings Yield (Greenblatt) (%) -7.90
CSII's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. CSII: -7.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CSII' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.9  Med: 32 Max: 5408.1
Current: -7.9
-7.9
5408.1

More Statistics

Revenue (TTM) (Mil) $178.2
EPS (TTM) $ -1.72
Beta2.69
Short Percentage of Float4.03%
52-Week Range $7.50 - 25.22
Shares Outstanding (Mil)33.35

Analyst Estimate

Jun17 Jun18
Revenue (Mil $) 204 235
EPS ($) -0.56 0.18
EPS w/o NRI ($) -0.56 0.18
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Stocks Mario Gabelli Has Bought for 2 Quarters Jun 20 2016 
Stocks Bill Frels Keeps On Buying Nov 17 2015 
Mairs & Power Small Cap Fund Comments on Cardiovascular Systems Oct 20 2014 
Mairs & Power Small Cap Fund Q3 2014 Commentary Oct 20 2014 
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley sells 5,663 Shares May 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Cardiovascular Systems (CSII): Portfolio Robust, Woes Stay Sep 12 2016
ETF’s with exposure to Cardiovascular Systems, Inc. : September 1, 2016 Sep 01 2016
Cardiovascular Systems Launches the Take A Stand Against Amputation Program in Time for September... Sep 01 2016
Cardiovascular Systems Launches the Take A Stand Against Amputation Program in Time for September... Sep 01 2016
CARDIOVASCULAR SYSTEMS INC Financials Aug 31 2016
Cardiovascular Systems, Inc. :CSII-US: Earnings Analysis: 2016 By the Numbers : August 31, 2016 Aug 31 2016
CARDIOVASCULAR SYSTEMS INC Files SEC form 10-K, Annual Report Aug 25 2016
Cardiovascular Systems (CSII) Catches Eye: Stock Up 5.6% Aug 23 2016
Cardiovascular Systems (CSII) Stock Closed Higher on Ratings Upgrade Aug 22 2016
Cardiovascular Systems upgraded by Leerink Partners Aug 22 2016
CARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Aug 16 2016
Cardiovascular Systems Names Scott Ward as CEO Aug 16 2016
Cardiovascular Systems Names Scott Ward as CEO Aug 16 2016
Cardiovascular Systems to Present at the Fifth Annual InvestMNt Conference Aug 15 2016
Cardiovascular Systems Releases 30-Day Results from Liberty 360° Study in Late-Breaking... Aug 11 2016
Cardiovascular Systems (CSII) Loss Narrows Y/Y in Q4 Aug 08 2016
Cardiovascular Systems reports 4Q loss Aug 03 2016
Cardiovascular Systems reports 4Q loss Aug 03 2016
Cardiovascular Systems Reports Fiscal 2016 Fourth-Quarter Financial Results Aug 03 2016
CARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)